Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Research Report 2025

Publication ID:

PB502253420

Publication Date:

February 13, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Sulfasalazine Enteric-Coated Tablets was valued at US$ 156 million in the year 2024 and is projected to reach a revised size of US$ 214 million by 2031, growing at a CAGR of 4.5% during the forecast period.
Sulfasalazine is used to treat ulcerative colitis, rheumatoid arthritis, and polyarticular-course juvenile rheumatoid arthritis, and works by lowering inflammation in the body, reducing pain and swelling.
North American market for Sulfasalazine Enteric-Coated Tablets is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Sulfasalazine Enteric-Coated Tablets is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Sulfasalazine Enteric-Coated Tablets include Pfizer, Teva Pharmaceuticals, Shanghai Pharmaceuticals, CR Double-Crane, Shanghai Sine Tianping Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sulfasalazine Enteric-Coated Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sulfasalazine Enteric-Coated Tablets.
The Sulfasalazine Enteric-Coated Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sulfasalazine Enteric-Coated Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sulfasalazine Enteric-Coated Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Pfizer
Teva Pharmaceuticals
Shanghai Pharmaceuticals
CR Double-Crane
Shanghai Sine Tianping Pharmaceutical
Segment by Type
0.25g
0.5g
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sulfasalazine Enteric-Coated Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sulfasalazine Enteric-Coated Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Overview
1.1 Product Definition
1.2 Sulfasalazine Enteric-Coated Tablets by Type
1.2.1 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 0.25g
1.2.3 0.5g
1.3 Sulfasalazine Enteric-Coated Tablets by Application
1.3.1 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Sulfasalazine Enteric-Coated Tablets Revenue 2020-2031
1.4.2 Global Sulfasalazine Enteric-Coated Tablets Sales 2020-2031
1.4.3 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Competition by Manufacturers
2.1 Global Sulfasalazine Enteric-Coated Tablets Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Sulfasalazine Enteric-Coated Tablets Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Sulfasalazine Enteric-Coated Tablets Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Sulfasalazine Enteric-Coated Tablets, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Sulfasalazine Enteric-Coated Tablets, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sulfasalazine Enteric-Coated Tablets, Product Type & Application
2.7 Global Key Manufacturers of Sulfasalazine Enteric-Coated Tablets, Date of Enter into This Industry
2.8 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Competitive Situation and Trends
2.8.1 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Sulfasalazine Enteric-Coated Tablets Players 麻豆原创 Share by Revenue
2.8.3 Global Sulfasalazine Enteric-Coated Tablets Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Scenario by Region
3.1 Global Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Sulfasalazine Enteric-Coated Tablets Sales by Region: 2020-2031
3.2.1 Global Sulfasalazine Enteric-Coated Tablets Sales by Region: 2020-2025
3.2.2 Global Sulfasalazine Enteric-Coated Tablets Sales by Region: 2026-2031
3.3 Global Sulfasalazine Enteric-Coated Tablets Revenue by Region: 2020-2031
3.3.1 Global Sulfasalazine Enteric-Coated Tablets Revenue by Region: 2020-2025
3.3.2 Global Sulfasalazine Enteric-Coated Tablets Revenue by Region: 2026-2031
3.4 North America Sulfasalazine Enteric-Coated Tablets 麻豆原创 Facts & Figures by Country
3.4.1 North America Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Sulfasalazine Enteric-Coated Tablets Sales by Country (2020-2031)
3.4.3 North America Sulfasalazine Enteric-Coated Tablets Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Sulfasalazine Enteric-Coated Tablets 麻豆原创 Facts & Figures by Country
3.5.1 Europe Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Sulfasalazine Enteric-Coated Tablets Sales by Country (2020-2031)
3.5.3 Europe Sulfasalazine Enteric-Coated Tablets Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sulfasalazine Enteric-Coated Tablets 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Sulfasalazine Enteric-Coated Tablets Sales by Region (2020-2031)
3.6.3 Asia Pacific Sulfasalazine Enteric-Coated Tablets Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Sulfasalazine Enteric-Coated Tablets 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Sulfasalazine Enteric-Coated Tablets Sales by Country (2020-2031)
3.7.3 Latin America Sulfasalazine Enteric-Coated Tablets Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Sulfasalazine Enteric-Coated Tablets 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Sulfasalazine Enteric-Coated Tablets 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Sulfasalazine Enteric-Coated Tablets Sales by Country (2020-2031)
3.8.3 Middle East and Africa Sulfasalazine Enteric-Coated Tablets Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Sulfasalazine Enteric-Coated Tablets Sales by Type (2020-2031)
4.1.1 Global Sulfasalazine Enteric-Coated Tablets Sales by Type (2020-2025)
4.1.2 Global Sulfasalazine Enteric-Coated Tablets Sales by Type (2026-2031)
4.1.3 Global Sulfasalazine Enteric-Coated Tablets Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Sulfasalazine Enteric-Coated Tablets Revenue by Type (2020-2031)
4.2.1 Global Sulfasalazine Enteric-Coated Tablets Revenue by Type (2020-2025)
4.2.2 Global Sulfasalazine Enteric-Coated Tablets Revenue by Type (2026-2031)
4.2.3 Global Sulfasalazine Enteric-Coated Tablets Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Sulfasalazine Enteric-Coated Tablets Price by Type (2020-2031)
5 Segment by Application
5.1 Global Sulfasalazine Enteric-Coated Tablets Sales by Application (2020-2031)
5.1.1 Global Sulfasalazine Enteric-Coated Tablets Sales by Application (2020-2025)
5.1.2 Global Sulfasalazine Enteric-Coated Tablets Sales by Application (2026-2031)
5.1.3 Global Sulfasalazine Enteric-Coated Tablets Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Sulfasalazine Enteric-Coated Tablets Revenue by Application (2020-2031)
5.2.1 Global Sulfasalazine Enteric-Coated Tablets Revenue by Application (2020-2025)
5.2.2 Global Sulfasalazine Enteric-Coated Tablets Revenue by Application (2026-2031)
5.2.3 Global Sulfasalazine Enteric-Coated Tablets Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Sulfasalazine Enteric-Coated Tablets Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Sulfasalazine Enteric-Coated Tablets Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Sulfasalazine Enteric-Coated Tablets Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Teva Pharmaceuticals
6.2.1 Teva Pharmaceuticals Company Information
6.2.2 Teva Pharmaceuticals Description and Business Overview
6.2.3 Teva Pharmaceuticals Sulfasalazine Enteric-Coated Tablets Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Teva Pharmaceuticals Sulfasalazine Enteric-Coated Tablets Product Portfolio
6.2.5 Teva Pharmaceuticals Recent Developments/Updates
6.3 Shanghai Pharmaceuticals
6.3.1 Shanghai Pharmaceuticals Company Information
6.3.2 Shanghai Pharmaceuticals Description and Business Overview
6.3.3 Shanghai Pharmaceuticals Sulfasalazine Enteric-Coated Tablets Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Shanghai Pharmaceuticals Sulfasalazine Enteric-Coated Tablets Product Portfolio
6.3.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.4 CR Double-Crane
6.4.1 CR Double-Crane Company Information
6.4.2 CR Double-Crane Description and Business Overview
6.4.3 CR Double-Crane Sulfasalazine Enteric-Coated Tablets Sales, Revenue and Gross Margin (2020-2025)
6.4.4 CR Double-Crane Sulfasalazine Enteric-Coated Tablets Product Portfolio
6.4.5 CR Double-Crane Recent Developments/Updates
6.5 Shanghai Sine Tianping Pharmaceutical
6.5.1 Shanghai Sine Tianping Pharmaceutical Company Information
6.5.2 Shanghai Sine Tianping Pharmaceutical Description and Business Overview
6.5.3 Shanghai Sine Tianping Pharmaceutical Sulfasalazine Enteric-Coated Tablets Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shanghai Sine Tianping Pharmaceutical Sulfasalazine Enteric-Coated Tablets Product Portfolio
6.5.5 Shanghai Sine Tianping Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sulfasalazine Enteric-Coated Tablets Industry Chain Analysis
7.2 Sulfasalazine Enteric-Coated Tablets Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sulfasalazine Enteric-Coated Tablets Production Mode & Process Analysis
7.4 Sulfasalazine Enteric-Coated Tablets Sales and 麻豆原创ing
7.4.1 Sulfasalazine Enteric-Coated Tablets Sales Channels
7.4.2 Sulfasalazine Enteric-Coated Tablets Distributors
7.5 Sulfasalazine Enteric-Coated Tablets Customer Analysis
8 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Dynamics
8.1 Sulfasalazine Enteric-Coated Tablets Industry Trends
8.2 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Drivers
8.3 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Challenges
8.4 Sulfasalazine Enteric-Coated Tablets 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
Teva Pharmaceuticals
Shanghai Pharmaceuticals
CR Double-Crane
Shanghai Sine Tianping Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.